Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin, Christine L. Hann, Edward B. Garon et al. · Clinical Cancer Research · 2012
PURPOSE: Bcl-2 is a critical regulator of apoptosis that is overexpressed in the majority of small cell lung cancers (SCLC). Nativoclax (ABT-263) is a potent and selective inhibitor of Bcl-2 and Bcl-x(L). The primary objectives of this phase IIa study included safety at the recommended phase II dose and preliminary, exploratory efficacy assessment in patients with recurrent and progressive SCLC after at least one prior therapy. EXPERIMENTAL DESIGN: Thirty-nine patients received navitoclax 325 mg daily, following an initial lead-in of 150 mg daily for 7 days. Study endpoints included safety and toxicity assessment, response rate, progression-free and overall survival (PFS and OS), as well as exploratory pharmacodynamic correlates. RESULTS: The most common toxicity associated with navitoclax was thrombocytopenia, which reached grade III-IV in 41% of patients. Partial response was observed in one (2.6%) patient and stable disease in 9 (23%) patients. Median PFS was 1.5 months and median OS was 3.2 months. A strong association between plasma pro-gastrin-releasing peptide (pro-GRP) level and tumor Bcl-2 copy number (R = 0.93) was confirmed. Exploratory analyses revealed baseline levels of cytokeratin 19 fragment antigen 21-1, neuron-specific enolase, pro-GRP, and circulating tumor cell number as correlates of clinical benefit. CONCLUSION: Bcl-2 targeting by navitoclax shows limited single-agent activity against advanced and recurrent SCLC. Correlative analyses suggest several putative biomarkers of clinical benefit. Preclinical models support that navitoclax may enhance sensitivity of SCLC and other solid tumors to standard cytotoxics. Future studies will focus on combination therapies.
Cited by 564 works. doi:10.1158/1078-0432.ccr-11-3090
Authors
- Charles M. Rudin
- Christine L. Hann
- Edward B. Garon
- Moacyr Ribeiro de Oliveira
- Philip Bonomi
- D. Ross Camidge
- Quincy Siu-Chung Chu
- Giuseppe Giaccone
- Divis K. Khaira
- Suresh S. Ramalingam
- Malcolm Ranson
- Caroline Dive
- Evelyn Mary McKeegan
- Brenda Chyla
- Barry L. Dowell
- Arunava Chakravartty
- Cathy E. Nolan
- Niki S. Rudersdorf
- Todd A. Busman
- Mack H. Mabry
References
- Bagging Predictors
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Bagging predictors
- An inhibitor of Bcl-2 family proteins induces regression of solid tumours
- The Bcl-2 apoptotic switch in cancer development and therapy
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
- Programmed Anuclear Cell Death Delimits Platelet Life Span
- Common Terminology Criteria for Adverse Events
- Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer